TY - JOUR
T1 - Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program
AU - Sruamsiri, Rosarin
AU - Chaiyakunapruk, Nathorn
AU - Pakakasama, Samart
AU - Sirireung, Somtawin
AU - Sripaiboonkij, Nintita
AU - Bunworasate, Udomsak
AU - Hongeng, Suradej
PY - 2013
Y1 - 2013
N2 - Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand.
AB - Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand.
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583808/pdf/1472-6963-13-45.pdf
U2 - 10.1186/1472-6963-13-45
DO - 10.1186/1472-6963-13-45
M3 - Article
SN - 1472-6963
VL - 13
SP - 1
EP - 12
JO - BMC Health Services Research
JF - BMC Health Services Research
IS - 1
M1 - 45
ER -